Fluorothymidine F-18

Phase 1Small molecule

MM.D. Anderson Cancer Center

Fluorothymidine F-18 is one of 105 small molecule programs targeting Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

104

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Soft Tissue SarcomaActive, not recruiting

Breast CancerPreclinical

Active, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

Soft Tissue SarcomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Trodelvy

Gilead

Preclinical

37 2

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 3

Megace

Bristol-Myers Squibb

Preclinical

4 4

Lexiscan

Astellas

Preclinical

1 5

Adenocard

Astellas

Preclinical

1 6

Blenoxane

Bristol-Myers Squibb

Preclinical

1 7

Lupron

EEastern Cooperative Oncology Group

Preclinical

5 8

Chirocaine

PPurdue Pharma LP

Preclinical

1 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Acute Myeloid Leukemia

NCT03422731

Clinical

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

Fluorothymidine F-18 PET in Diagnosing Patients With Intermediate or High Grade Soft Tissue Sarcoma

Withdrawn·OOHSU Knight Cancer Institute·Phase 1·NCT03613259

Advanced Malignancies1 trial

FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00880074·10 enrolled

Acute Myeloid Leukemia1 trial

Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy

Recruiting·—·Phase 1·NCT03422731·74 enrolled

PET/CT Imaging1 trial

[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers

Completed·—·Phase 2·NCT01717391·36 enrolled

Breast Cancer1 trial

FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer

Completed·UUniversity of Washington·N/A·NCT01928186·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Fluorothymidine F-18. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluorothymidine F-18 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluorothymidine F-18. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MM.D. Anderson Cancer Center

Fluorothymidine F-18

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Soft Tissue Sarcoma1 trial

Advanced Malignancies1 trial

Acute Myeloid Leukemia1 trial

PET/CT Imaging1 trial

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News